More about

Adalimumab

News
January 17, 2023
13 min read
Save

Humira exclusivity expires in 2023: Will biosimilar boom benefit patients or industry?

Humira exclusivity expires in 2023: Will biosimilar boom benefit patients or industry?

In 2021, Humira — the blockbuster biologic that has for years been the highest grossing drug in the world — accomplished something that no drug had previously achieved when its global revenues topped $20 billion.

News
January 11, 2023
2 min read
Save

Etanercept, adalimumab improve wellbeing in non-systemic juvenile idiopathic arthritis

Etanercept, adalimumab improve wellbeing in non-systemic juvenile idiopathic arthritis

Etanercept and adalimumab are both impactful at improving the health of patients with non-systemic juvenile idiopathic arthritis, according to data published in Pediatric Rheumatology.

News
December 23, 2022
1 min read
Save

Top in rheumatology: Adalimumab biosimilar approval; the immunopathophysiology of PsA

Top in rheumatology: Adalimumab biosimilar approval; the immunopathophysiology of PsA

The FDA approved Idacio as a biosimilar to Humira, a TNF inhibitor with indications for rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis and plaque psoriasis.

News
December 20, 2022
14 min read
Save

Hoping for a biosimilar ‘sea change’: Rheumatologists weigh 2023 end of Humira exclusivity

Hoping for a biosimilar ‘sea change’: Rheumatologists weigh 2023 end of Humira exclusivity

In 2021, Humira, the blockbuster biologic that has for years been the highest grossing drug in the world, accomplished something that no drug had previously achieved when its global revenues topped $20 billion.

News
December 15, 2022
2 min read
Save

Cigna Pharmacy to list adalimumab biosimilars at same price point as originator

Cigna Pharmacy to list adalimumab biosimilars at same price point as originator

Cigna Pharmacy announced that it will add adalimumab biosimilars as “preferred products” at the same price level as the originator Humira on its commercial formularies, according to a company press release.

News
December 14, 2022
1 min read
Save

FDA approves Fresenius Kabi’s Idacio as eighth adalimumab biosimilar

FDA approves Fresenius Kabi’s Idacio as eighth adalimumab biosimilar

The FDA has approved Idacio as the eighth biosimilar to adalimumab, for all eligible indications of the reference product, clearing the way for its U.S. release in 2023 alongside a deluge of other Humira biosimilars.

News
November 30, 2022
2 min read
Save

Switching from adalimumab to upadacitinib demonstrates clinical improvement for patients with RA

Switching from adalimumab to upadacitinib demonstrates clinical improvement for patients with RA

PHILADELPHIA — An early switch from adalimumab to upadacitinib due to non-response demonstrated clinical improvement among patients with rheumatoid arthritis, according to data presented at ACR Convergence 2022.

News
November 29, 2022
2 min read
Save

Upadacitinib effective in patients with RA who failed prior TNF inhibitor therapy

Upadacitinib effective in patients with RA who failed prior TNF inhibitor therapy

PHILADELPHIA — Among patients with rheumatoid arthritis who had an inadequate response or intolerance to TNF inhibitors, upadacitinib demonstrated clinically meaningful and improved efficacy over 24 weeks, according to a post-hoc analysis.

News
November 28, 2022
2 min read
Save

Upadacitinib shows greater improvement in PsA compared with adalimumab, placebo

Upadacitinib shows greater improvement in PsA compared with adalimumab, placebo

PHILADELPHIA — In patients with psoriatic arthritis, upadacitinib showed greater improvement compared with both placebo and adalimumab as assessed by the Routine Assessment of Patient Index Data 3, or RAPID3, scores.

News
October 21, 2022
1 min read
Save

Top in GI: Controversial colonoscopy data; biosimilars effective for IBD

Top in GI: Controversial colonoscopy data; biosimilars effective for IBD

The American Gastroenterology Association recently spoke out about data that showed colonoscopy screening had a modest benefit in colorectal cancer.

View more